Orphan Drugs (German, Paperback)

"The promotion and development of medicinal products for the treatment of rare diseases require our particular attention, as health is our most valuable possession," said Ursula Schleicher, former Vice-President of the European Parliament. According to estimates, around 25 million people in Europe are suffering from 5,000 to 8,000 orphan diseases. Many of them are still waiting for medicines that will allow them to at least be able to lead a pain-free life, if not always a normal life. From a purely business-management viewpoint, the development of drugs for rare diseases is not always economical for the pharmaceutical industry. Nor can sufferers raise the funds themselves for research into the drugs that for them are vitally necessary. It is, therefore, a question of moral values and national priorities as to what extent society is prepared to help those affected. In 1999 the European Union adopted the Orphan Medicinal Products Regulation. This offers the biopharmaceutical and pharmaceutical industry incentives to develop orphan drugs. This book presents the European Orphan Medicinal Products Regulation and compares it with the rules of other countries. It also discusses the possibilities of creating further incentives.

General

Imprint:	Health Economics Research Zentrum (Herz)
Country of origin:	United States
Release date:	June 2005
First published:	June 2005
Authors:	Daniel Hagn • Oliver Schoeffski
Dimensions:	210 x 148 x 9mm (L x W x T)
Format:	Paperback - Trade
Pages:	160
ISBN-13:	978-3-936863-05-5
Languages:	German
Categories:	Books > Medicine > Nursing & ancillary services > Pharmacy / dispensing Promotions
LSN:	3-936863-05-9
Barcode:	9783936863055

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!